 EAST SETAUKET, New York, April 13, 2021 GLOBE NEWSWIRE -- Lixte Biotechnology Holdings, Inc. Lixte or the Company Nasdaq: LIXT , a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, announced the appointment of Gil N Schwartzberg to its Board of Directors. Mr. Schwartzberg is filling a vacancy created by the resignation of Winson Sze Chun Ho, M.D. 